Literature DB >> 19337287

Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis.

Kristine Phillips1, Cathryn Byrne-Dugan, Eric Batterson, James R Seibold.   

Abstract

BACKGROUND: A 36-year-old woman developed new-onset Raynaud phenomenon and rapidly progressive dyspnea over a 2-week period. A lung biopsy demonstrated pauci-inflammatory nonspecific pneumonitis, which proved refractory to systemic corticosteroid and intravenous cyclophosphamide therapy. Her preterminal course in an intensive care unit was typified by sequential organ failure. Postmortem examination showed extensive organ fibrosis, including severe diffuse alveolar damage and parenchymal fibrosis, and a notable lack of potentially treatable tissue inflammation. INVESTIGATIONS: Chest radiography, physical examination, screening for autoantibodies, measurement of serum creatinine, creatine phosphokinase, and brain natriuretic peptide levels, cardiac examination, pulmonary function tests, electrocardiography, transthoracic Doppler echocardiography, right heart catheterization, high-resolution thoracic CT, pulmonary ventilation/perfusion scan, lung biopsy. DIAGNOSIS: Interstitial lung disease associated with diffuse systemic sclerosis. MANAGEMENT: Treatment with oxygen, oral and intravenous corticosteroids, mycophenolate mofetil and intravenous cyclophosphamide.

Entities:  

Mesh:

Year:  2009        PMID: 19337287     DOI: 10.1038/nrrheum.2009.30

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  17 in total

1.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

2.  Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?

Authors:  Athol U Wells; Panagiota Latsi; W Joseph McCune
Journal:  Am J Respir Crit Care Med       Date:  2007-11-15       Impact factor: 21.405

3.  Scleroderma lung disease: "if you don't know where you are going, any road will take you there".

Authors:  Charlie Strange; James R Seibold
Journal:  Am J Respir Crit Care Med       Date:  2008-06-01       Impact factor: 21.405

4.  Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.

Authors:  Sotiris C Plastiras; Stylianos P Karadimitrakis; Panayiotis D Ziakas; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos; George E Tzelepis
Journal:  Arthritis Rheum       Date:  2006-08-15

5.  Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis.

Authors:  Predrag Ostojić; Nemanja Damjanov
Journal:  Clin Rheumatol       Date:  2006-04-28       Impact factor: 2.980

Review 6.  The spectrum of scleroderma lung disease.

Authors:  Kristin B Highland; Margaret C Garin; Kevin K Brown
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

7.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

Review 8.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

9.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.

Authors:  Vivien M Hsu; Abel E Moreyra; Alan C Wilson; Meir Shinnar; Daniel M Shindler; Julianne E Wilson; Ami Desai; James R Seibold
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

10.  Interstitial lung disease in systemic sclerosis: a simple staging system.

Authors:  Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.